Matthew R Smith1. 1. Division of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. smith.matthew@mgh.harvard.edu
Abstract
PURPOSE: To evaluate effects of obesity on sex steroid levels during treatment with a gonadotropin-releasing hormone agonist in men with prostate cancer. EXPERIMENTAL DESIGN: Forty-nine hormone-naïve men with recurrent or locally advanced prostate cancer were included in the analyses. All subjects were treated with leuprolide 3-month depot for 48 weeks. Serum levels of estradiol, sex hormone-binding globulin, total testosterone, and free testosterone were assessed at baseline, 24 weeks, and 48 weeks. Subjects were categorized by body mass index (BMI) and percent body fat. RESULTS: Pretreatment serum sex hormone-binding globulin and total testosterone levels were significantly lower in overweight and obese men than in men with normal BMI. In the overall study population, mean serum testosterone concentrations decreased from 372 +/- 18 ng/dL at baseline to 13 +/- 1 ng/dL at week 48 (P < 0.001). Free testosterone decreased from 6.75 +/- 0.33 ng/dL at baseline to 0.21 +/- 0.02 ng/dL at week 48 (P < 0.001). During treatment with leuprolide, obese men had significantly higher total and free testosterone levels than men with normal BMI. Compared with normal men, total and free testosterone levels during treatment were 1.8-fold and 2.3-fold higher in obese men. Similar results were observed when subjects were categorized by body fat. CONCLUSIONS: Despite lower pretreatment serum testosterone levels, obese men have higher total and free testosterone levels during leuprolide treatment than men with normal BMI. These differences may contribute to the association between obesity and increased prostate cancer mortality.
PURPOSE: To evaluate effects of obesity on sex steroid levels during treatment with a gonadotropin-releasing hormone agonist in men with prostate cancer. EXPERIMENTAL DESIGN: Forty-nine hormone-naïve men with recurrent or locally advanced prostate cancer were included in the analyses. All subjects were treated with leuprolide 3-month depot for 48 weeks. Serum levels of estradiol, sex hormone-binding globulin, total testosterone, and free testosterone were assessed at baseline, 24 weeks, and 48 weeks. Subjects were categorized by body mass index (BMI) and percent body fat. RESULTS: Pretreatment serum sex hormone-binding globulin and total testosterone levels were significantly lower in overweight and obesemen than in men with normal BMI. In the overall study population, mean serum testosterone concentrations decreased from 372 +/- 18 ng/dL at baseline to 13 +/- 1 ng/dL at week 48 (P < 0.001). Free testosterone decreased from 6.75 +/- 0.33 ng/dL at baseline to 0.21 +/- 0.02 ng/dL at week 48 (P < 0.001). During treatment with leuprolide, obesemen had significantly higher total and free testosterone levels than men with normal BMI. Compared with normal men, total and free testosterone levels during treatment were 1.8-fold and 2.3-fold higher in obesemen. Similar results were observed when subjects were categorized by body fat. CONCLUSIONS: Despite lower pretreatment serum testosterone levels, obesemen have higher total and free testosterone levels during leuprolide treatment than men with normal BMI. These differences may contribute to the association between obesity and increased prostate cancer mortality.
Authors: Eric Orwoll; Lori C Lambert; Lynn M Marshall; Kathy Phipps; Janet Blank; Elizabeth Barrett-Connor; Jane Cauley; Kris Ensrud; Steve Cummings Journal: J Clin Endocrinol Metab Date: 2005-12-20 Impact factor: 5.958
Authors: Juan Morote; Salvador Esquena; José M Abascal; Enrique Trilla; Luis Cecchini; Carles X Raventós; Roberto Catalán; Jaume Reventós Journal: Urol Int Date: 2006 Impact factor: 2.089
Authors: Cynthia L Ogden; Margaret D Carroll; Lester R Curtin; Margaret A McDowell; Carolyn J Tabak; Katherine M Flegal Journal: JAMA Date: 2006-04-05 Impact factor: 56.272
Authors: A Tchernof; J P Després; A Bélanger; A Dupont; D Prud'homme; S Moorjani; P J Lupien; F Labrie Journal: Metabolism Date: 1995-04 Impact factor: 8.694
Authors: Jason A Efstathiou; Kyounghwa Bae; William U Shipley; Gerald E Hanks; Miljenko V Pilepich; Howard M Sandler; Matthew R Smith Journal: Cancer Date: 2007-12-15 Impact factor: 6.860
Authors: P Pérez-Segura; J E Palacio; L Vázquez; S Monereo; R de Las Peñas; P Martínez de Icaya; C Grávalos; A Lecube; A Blasco; J M García-Almeida; I Barneto; A Goday Journal: Clin Transl Oncol Date: 2017-01-10 Impact factor: 3.405
Authors: Heather Greenlee; Joseph M Unger; Michael LeBlanc; Scott Ramsey; Dawn L Hershman Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-12-16 Impact factor: 4.254
Authors: Christopher J Keto; William J Aronson; Martha K Terris; Joseph C Presti; Christopher J Kane; Christopher L Amling; Stephen J Freedland Journal: Eur Urol Date: 2012-12-06 Impact factor: 20.096
Authors: Eija A Lundström; Rupert K Rencken; Johann H van Wyk; Lance J E Coetzee; Johann C M Bahlmann; Simon Reif; Erdam A Strasheim; Martin C Bigalke; Alan R Pontin; Louis Goedhals; Douw G Steyn; Chris F Heyns; Luigi A Aldera; Thomas M Mackenzie; Daniela Purcea; Pierre Y Grosgurin; Hervé C Porchet Journal: Clin Drug Investig Date: 2009 Impact factor: 2.859